Opioid prescription for severe chronic breathlessness to hospitalised patients with COPD - a clinical audit Source: Virtual Congress 2020 – Clinical data and COPD management Year: 2020
Late Breaking Abstract - Does medication exacerbate comorbidities in chronic obstructive pulmonary disease? A prevalence study of neuroleptic intake Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018
Impacting patient-centred outcomes in COPD: exacerbations and hospitalisations Source: Eur Respir Rev 2006; 15: 47-51 Year: 2006
May the obesity cause a better prognosis for domiciliary NIV prescribed COPD patients? Source: International Congress 2015 – Outcome of noninvasive ventilatory support in acute and chronic respiratory failure Year: 2015
Opioids in COPD: a cause of death or a marker of illness severity? Source: Eur Respir J 2016; 48: 1520-1521 Year: 2016
Opioids in COPD: a cause of death or a marker of illness severity? Source: Eur Respir J 2016; 48: 1521-1522 Year: 2016
Assessing COPD profiles and outcomes by dyspnoea severity Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Prescription of opioids for breathlessness in end-stage chronic obstructive pulmonary disease: A national population based study Source: International Congress 2016 – Management of dyspnoea and exacerbations in chronic lung diseases Year: 2016
Pulmonary rehabilitation following hospitalisation for acute exacerbation of COPD: Fact or fiction? Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation Year: 2013
Enough is enough: misuse of NIV in the treatment of chronic patients with exacerbation of symptoms? Source: Annual Congress 2013 –The dark side of the moon: when, why, and where I should not use NIV? Year: 2013
Characteristics and medication use of the patients with acute exacerbations of asthma-COPD overlap syndrome Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015
Respiratory depression secondary to morphine use in a patient with COPD and refractory breathlessness Source: Eur Respir J, 49 (5) 1601858; 10.1183/13993003.01858-2016 Year: 2017
Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD Source: Eur Respir J 2009; 33: 282-288 Year: 2009
Missed opportunity? Worsening breathlessness as a harbinger of death: a cohort study Source: Eur Respir J, 52 (3) 1800684; 10.1183/13993003.00684-2018 Year: 2018
Prescription opioid use in advanced COPD: benefits, perils and controversies Source: Eur Respir J, 49 (6) 1700690; 10.1183/13993003.00690-2017 Year: 2017
Prescription opioid use in advanced COPD: benefits, perils and controversies Source: Eur Respir J, 49 (6) 1700479; 10.1183/13993003.00479-2017 Year: 2017
Comorbidities – should we and how should we treat them in asthma and COPD? Source: International Congress 2014 – PG02 Current clinical problems in pulmonology Year: 2014
Is it safe to prescribe benzodiazepines or opioids for dyspnoea in interstitial lung disease? Source: Breathe, 15 (2) 137; 10.1183/20734735.0015-2019 Year: 2019
Changes in cognitive status during acute exacerbation of COPD Source: International Congress 2015 – Rehabilitation, exercise, hospitalisation and COPD Year: 2015